News
A quarter of cancer patients experience avoidable delay to diagnosis
One in four cancer patients experienced a delay to their diagnosis that could have been avoided, according to a new study by Cancer Research UK. It found that nearly 3,400 of 14,300 patients experienced a delay…
So-called ‘junk DNA’ affects inherited cancer risk
A person’s risk of developing cancer is affected by genetic variations in regions of DNA that don’t code for proteins, previously dismissed as ‘junk DNA’, according to new research published in the British Journal of Cancer. This…
Targeted ovarian cancer drug made more widely available on the NHS in Scotland
A targeted cancer drug has been approved for use on the NHS in Scotland for patients with advanced, newly diagnosed ovarian cancer that’s responded to chemotherapy. Olaparib (Lynparza) tablets will be used to help prolong the…
Targeted ovarian cancer drug made available to more people on NHS in England
The National Institute for Health and Care Excellence (NICE) has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. Trial results have shown that olaparib, which stops cancer…
Blood test can quickly match advanced breast cancer patients to targeted treatments
A blood test can help identify rare mutations in advanced breast cancer, which may enable patients to access effective treatments more quickly in the future, Cancer Research UK scientists have found. As part of the plasmaMATCH clinical trial,…
